Fate Therapeutics (FATE) Current Deferred Revenue (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Current Deferred Revenue came in at $582000.0 in Q1 2026, up 174.53% YoY from $212000.0 in Q1 2025, and up 52.76% on a QoQ basis from $381000.0 in Q4 2025.
Fate Therapeutics (FATE) Current Deferred Revenue (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Current Deferred Revenue data on file, last reported at $582000.0 in Q1 2026.
- Quarterly Current Deferred Revenue rose 174.53% year-over-year to $582000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $582000.0 (up 174.53% YoY) and the FY2025 annual result came in at $381000.0, down 3.05% from the prior year.
- Current Deferred Revenue improved to $582000.0 in Q1 2026, from $381000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $42.2 million in Q4 2022 to a low of $5000.0 in Q3 2025.
- A 5-year average of $9.4 million and a median of $685000.0 in 2023 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2025 — Current Deferred Revenue slumped 99.17% — and 2026, when it jumped 174.53%.
- Tracing FATE's Current Deferred Revenue over 5 years: stood at $42.2 million in 2022, then slumped by 98.38% to $685000.0 in 2023, then sank by 42.63% to $393000.0 in 2024, then dropped by 3.05% to $381000.0 in 2025, then soared by 52.76% to $582000.0 in 2026.
- The last three Current Deferred Revenue figures came in at $582000.0 (Q1 2026), $381000.0 (Q4 2025), and $5000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 582,000.00 |
| Dec 31, 2025 | 381,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Mar 31, 2025 | 212,000.00 |
| Dec 31, 2024 | 393,000.00 |
| Sep 30, 2024 | 600,000.00 |
| Mar 31, 2024 | 159,000.00 |
| Dec 31, 2023 | 685,000.00 |
| Sep 30, 2023 | 1.11 Mn |
| Jun 30, 2023 | 1.93 Mn |
| Mar 31, 2023 | 1.74 Mn |
| Dec 31, 2022 | 42.23 Mn |
| Sep 30, 2022 | 35.24 Mn |
| Jun 30, 2022 | 33.66 Mn |
| Mar 31, 2022 | 22.58 Mn |
| Dec 31, 2021 | 21.48 Mn |
| Sep 30, 2021 | 23.55 Mn |
| Jun 30, 2021 | 23.03 Mn |
| Mar 31, 2021 | 21.03 Mn |
| Dec 31, 2020 | 21.14 Mn |